beta
APGNW
Apexigen Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by apximab™, the company’s proprietary antibody drug discovery platform. its lead immuno-oncology drug candidate, apx005m, is a potent immune-activating antibody against cd40 currently in phase 2 clinical development.
Market Cap: 9.57 Million
Primary Exchange: NASDAQ
Shares Outstanding: 2.88 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 324 trading days
From: 2022-08-08 To: 2023-08-22
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|